Table 3 Summary of secondary efficacy endpoints (efficacy population)
|  | Placebo (N = 19) | Eclitasertib 600 mg (N = 41) | Ratio (95%CI) |
|---|---|---|---|
Number of days without need for oxygen Support and alive (days) | Â | Â | Â |
 Mean (SD) | 18.0 (10.2) | 20.5 (7.7) | 0.85 (0.57 to 1.29) |
 Median | 22.0 | 23.0 |  |
Number of ventilator-free days and alive (days) | Â | Â | Â |
 Mean (SD) | 23.4 (10.0) | 26.0 (7.4) | 0.70 (0.41 to 1.19) |
 Median | 28.0 | 28.0 |  |
Mortality at 28 days, n(%) | 2 (10.5%) | 2 (5%) | 0.46 (0.07 to 3.06) |
Number of respiratory failure-free days and alive (days) | Â | Â | Â |
 Mean (SD) | 23.3 (10.0) | 25.9 (7.4) | 0.69 (0.41 to 1.16) |
 Median | 28.0 | 28.0 |  |
Number (%) of patients receiving treatments up to Day 28 | Â | Â | Â |
Antithrombotics | 8 (42.1) | 20 (48.8) | Â |
 Prophylaxis | 8 (42.1) | 18 (43.9) |  |
 Adverse event | 0 | 3 (7.3) |  |
 Vasopressor | 3 (15.8) | 1 (2.4) |  |